Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator.
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam.
Santhera receives first product approval: Health Canada approves Catena® for treatment of Friedreich's ataxia
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Oligodendrocytes and the early multiple sclerosis lesion.
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.
High-field imaging of neurodegenerative diseases.
Dispositional optimism is unidimensional or bidimensional? The Portuguese revised Life Orientation Test.
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis.
Low-contrast visual tests reveal better alemtuzumab efficacy
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
DemTect, PANDA, EASY, and MUSIC: Cognitive Screening Tools with Age Correction and Weighting of Subtests According to Their Sensitivity and Specificity.
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Transcriptomics: mRNA and alternative splicing.
[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].
Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages.

Pages